The NCT03608618 trial is a phase 1, first-in-human, dose-escalation study assessing MCY-M11, a mesothelin-targeting CAR-M therapy, in patients with advanced ovarian cancer and malignant peritoneal mesothelioma (Figure 5). Here, MSLN is linked to ovarian cancer.